CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2046 for heart failure after acute myocardial infarction.
Cutaneous melanoma nearly always arises on parts of the body that receive abundant sun but, rarely, it can arise on parts that do not, such as the palms of the hands or soles of the feet. These rare cases of acral and mucosal melanomas, which often feature mutations in the transmembrane tyrosine kinase KIT, do not respond to current melanoma therapies.
Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed by researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, the world-first study found mice treated with the antiviral compound were protected from long-term brain and lung dysfunction, which are key symptoms of long COVID.
Scientists at Zai Lab (Shanghai) Co. Ltd. and Zai Lab (US) LLC have described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has identified androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism, polycystic ovary syndrome, precocious puberty, spinal and bulbar muscle atrophy, and age-related macular degeneration.
Oxford University Innovations Ltd. has synthesized hypoxia-activated proteolysis targeting chimeras (hypoxia-activated PROTACs; HAP-TAC) comprising a hypoxia-activated moiety modified E3 ubiquitin ligase-binding moiety coupled to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.
Shanghai Yidi Biotechnology Co. Ltd. has disclosed neutrophil elastase (ELANE; leukocyte elastase) inhibitors reported to be useful for the treatment of pain and respiratory tract inflammation.
Researchers from Lund University and collaborators have investigated the potential of selectively targeting TUBG1 as a therapeutic strategy in cancer treatment.
In a newly published study, researchers from the CSIR Institute of Genomics and Integrative Biology and collaborators further explored the potential of Cdk5 targeting as a therapeutic approach for type 2 diabetes and cognitive deterioration.
RSS
